Ketamine: Anesthesia, Depression Evidence, Dependence and Safety

Injectable ketamine is licensed for anesthesia in appropriate diagnostic and surgical settings. The cited UK Ketalar product information does not license it as a long-term psychiatric treatment. The FDA’s 2026 regulatory statements likewise distinguish approved ketamine anesthesia products from psychiatric uses, which are not FDA-approved. A clinician may discuss off-label treatment, but should explain the evidence, alternatives and additional uncertainties. [1] [2]

Ask exactly what is being proposed: the active medicine, route, formulation, indication and responsible clinician. The phrase ketamine therapy can describe very different services. An explanation should make clear whether the recommendation is supported by a particular trial, a local specialist protocol or a more uncertain extrapolation. Inclusion in this directory is not a statement that Cogniful provides the treatment.

Ketamine is a mixture of two molecular forms, while esketamine is one of those forms and has its own products and regulatory conditions. Spravato is a distinct intranasal esketamine medicine. Evidence or authorization for Spravato should not be copied onto a compounded ketamine spray, lozenge or injection. The esketamine guide addresses that separate medicine.

When comparing options, request the actual product information rather than accepting a shared drug-family name as proof of equivalence. A different route can alter exposure, predictability and monitoring requirements. A clinic should also explain who will communicate with the existing psychiatrist, especially when a new service is being added rather than replacing ongoing care.

A randomized trial published in the New England Journal of Medicine compared ketamine with electroconvulsive therapy in selected adults with nonpsychotic treatment-resistant major depression. Ketamine met the study’s noninferiority criterion for the initial treatment phase. The population, open-label design and limited initial treatment period matter: this is not proof that ketamine is preferable for every depressed person, psychotic depression or every emergency presentation. [3]

Research outcomes should be translated into a realistic personal discussion. Ask what would count as response, how it would be measured and what happens if improvement is brief or absent. A rapid change in feelings during a session is not the same as durable recovery in daily life. Maintaining improvement, managing recurrence and coordinating other treatment need their own plan.

Bring a chronological treatment history, including medicines tried, duration, tolerability, psychological treatments and the reasons each was stopped. Include any episodes of elevated mood, psychosis, previous substance-related harm or unexplained changes in consciousness. The aim is not to qualify for a fashionable treatment but to establish the diagnosis and the most appropriate next step.

Ask how cardiovascular health, liver problems, urinary symptoms and other medicines will be reviewed. Clarify the team’s emergency capabilities and how clinical responsibility is maintained between sessions. A persuasive description of potential benefit does not replace information about adverse-event management, follow-up or what happens if the treatment must be stopped.

Ketamine can cause dissociation, altered perception, dream-like experiences, dizziness, nausea and changes in blood pressure or heart rate. Recovery can include confusion or distressing emergence reactions. Respiratory support and trained monitoring are part of anesthetic use, and severe breathing problems remain possible. A calm-looking or dissociated person still needs appropriate observation. [1]

Before treatment, discuss how you will communicate discomfort and what assistance is available if an experience becomes frightening. Arrange transport and practical support according to the clinical instructions. Do not assume that feeling more alert means it is safe to drive, care for a child alone or undertake hazardous work. Follow the actual product and service’s recovery restrictions.

Compounded medicines are not FDA-approved products. The FDA does not evaluate their safety, effectiveness and quality before marketing in the same way as an approved medicine. Compounding may address a specific medical need, but that does not establish that a compounded psychiatric ketamine product has an approved indication or an evidence-based home-use regimen. [4]

Be cautious about claims that monitoring is unnecessary or that a product is equivalent to a licensed nasal medicine. Ask who prescribed it, which pharmacy prepared it, how the concentration is verified and what clinical support exists. Do not use a recreational or informally obtained substance as a substitute. This guide does not provide self-administration instructions or dose conversions.

Repeated or prolonged ketamine exposure has been associated with urinary-tract injury and liver or biliary problems, particularly in reports involving heavy or nonmedical use. Painful or frequent urination, blood in urine, abdominal pain or jaundice needs medical assessment. These symptoms should not be treated by simply continuing ketamine to dull the discomfort. [1]

Tell the clinician about the pattern and source of exposure honestly. A complete history helps determine the appropriate investigations and referrals. A person may need addiction care, urological assessment and mental health support together. Reducing stigma is useful because hiding the exposure can delay recognition of a medicine-related injury.

Alcohol, opioids, benzodiazepines and other sedating medicines can increase impairment or breathing risk. Other treatments may affect cardiovascular responses or recovery. Give the anesthetic or psychiatric team the full list of medicines and substances, including those used only occasionally. Do not stop established psychiatric treatment independently in order to follow an online ketamine protocol. [1]

Medication changes should be agreed between the clinicians involved. Ask which treatment continues, whether additional observation is needed and how to report symptoms after leaving the clinical setting. If several services give conflicting advice, seek clarification rather than trying to combine the instructions yourself.

Ketamine can be misused, and repeated use can be associated with tolerance and dependence. Concerns include escalating use, craving, difficulty controlling the pattern and continuing despite physical, psychological or social harm. Anxiety, insomnia, dysphoria and disorientation have been described in relation to misuse. Assessment should consider both the substance pattern and the symptoms that may have preceded it. [1]

There is no single home detox schedule that this guide can recommend. A care plan should assess other substances, physical complications and immediate safety. Someone also dependent on alcohol or benzodiazepines may face additional withdrawal risks requiring specific medical management. Do not replace ketamine with borrowed sedatives or another unreviewed drug to manage distress.

Research into psychiatric and addiction-related applications should be distinguished from an established, universally approved detox indication. A study involving a selected population and a structured therapeutic program does not show that ketamine alone treats every substance-use disorder. Ask what evidence applies to the proposed condition, what remains experimental and how the plan compares with established care.

For someone with a ketamine-use problem, continuing treatment should address craving, triggers, pain, mood and practical support rather than ending when use stops. Agree follow-up contacts and a response to recurrence. The co-occurring care guide explains why psychiatric and addiction needs should be considered together.

Immediate suicidal danger, severe confusion, a seizure, collapse or serious breathing difficulty requires emergency assessment. Do not wait for a scheduled treatment session or an admissions response. A promise of rapid benefit must not delay a safe setting for someone who cannot remain safe. A clinician should explain how emergency care fits with any longer-term proposal.

When the situation is not an emergency, describe changes in sleep, hopelessness, agitation and functioning promptly. Include whether an improvement has faded between sessions. The treatment team should use that information to reassess the plan rather than assuming that more exposure is always the answer.

Ask for a written explanation of the proposed indication, source of medicine, monitoring arrangements and alternatives. Clarify the distinction between a medically supervised procedure and a broader psychotherapy package. Ask who is qualified to manage an adverse reaction and who remains responsible for depression treatment after the course ends.

Keep expectations specific. An appropriate goal may be improved ability to engage in daily life or ongoing therapy, not a guaranteed cure or a requirement to have a particular subjective experience. A review should consider meaningful benefit and harm together, including cost, travel, caregiving needs and continuity with existing care.

Does off-label mean no evidence exists?

No. It means the proposed use is outside the product’s authorization. Some uses have clinical research, but evidence quality, population and monitoring still need explanation. Off-label should not be presented as synonymous with either proven benefit or inevitable harm.

Can I substitute a ketamine lozenge for esketamine?

No. They are different products with different evidence and administration requirements. Do not convert doses or routes yourself.

What matters after initial improvement?

Agree how response will be followed, which other treatments continue, who responds to deterioration and what the next step will be if benefit is not sustained. Continuing care is part of the decision from the outset.

1. Ketalar: UK product information.
2. FDA: 2026 regulatory statement on ketamine products and psychiatric claims.
3. Anand and colleagues: Ketamine versus ECT for nonpsychotic treatment-resistant major depression.
4. FDA: Compounding questions and answers.